In a recent transaction, the Chief Legal Officer of 4D Molecular Therapeutics, Inc. (NASDAQ:FDMT), Bizily Scott, sold shares worth over $44,000. The sale was executed in multiple trades with prices ranging from $25.342 to $25.7543 per share.
The transactions, which took place on May 16, 2024, involved the sale of 1,750 shares of common stock, yielding a total of approximately $44,541. These sales were conducted under a 10b5-1 trading plan that Scott had adopted on October 10, 2023.
In addition to the sales, Scott also acquired shares through the exercise of stock options. A total of 1,750 shares were acquired with option exercise prices between $6.49 and $8.04, amounting to a total transaction value of $13,294.
Following these transactions, Scott's ownership in the company stands at 3,487 shares of common stock directly held. The details of these transactions come from the latest Form 4 filing with the Securities and Exchange Commission, which provides insights into the trading activities of the company's insiders.
Investors often monitor insider transactions as they can provide indications of executives' confidence in the company's prospects. However, it's important to note that these transactions do not necessarily signal a change in company fundamentals and can be subject to various personal financial considerations.
InvestingPro Insights
4D Molecular Therapeutics, Inc. (NASDAQ:FDMT) has recently witnessed notable insider trading activity, which can often be a valuable indicator for investors. In light of these events, let's consider some key financial metrics and expert analysis from InvestingPro that may offer additional context to the insider transactions.
InvestingPro Data highlights a significant revenue growth of 826.31% for the last twelve months as of Q1 2024. Despite this surge, the company's gross profit margin stands at a concerning -401.41% for the same period, suggesting that the company's costs have far exceeded its revenue. Additionally, FDMT's market capitalization is currently valued at 1340M USD, providing investors with a sense of the company's size in the marketplace.
Among the InvestingPro Tips, it's notable that analysts are not optimistic about the company's profitability in the near term, as they do not anticipate the company will be profitable this year. This aligns with the company's negative P/E ratio of -10.74, which further emphasizes the lack of expected earnings. Moreover, FDMT's stock price has experienced significant volatility, with a large price uptick of 117.57% over the last six months, which may be an important consideration for investors looking for stable investments.
For investors seeking a deeper dive into the financial health and future prospects of 4D Molecular Therapeutics, InvestingPro offers additional insights and metrics. There are 10 more InvestingPro Tips available, which can be accessed at https://www.investing.com/pro/FDMT. Investors interested in leveraging these insights can use the coupon code PRONEWS24 to get an additional 10% off a yearly or biyearly Pro and Pro+ subscription.
It's essential for investors to examine both the insider trading activity and the broader financial context to make informed decisions. The metrics and analysis provided by InvestingPro can serve as a valuable tool in this regard.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.